Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

被引：765

作者：

Falavarjani, K. Ghasemi ^{[1
]}

Nguyen, Q. D. ^{[2
]}

机构：

[1] Univ Tehran Med Sci, Rassoul Akram Hosp, Eye Res Ctr, Dept Ophthalmol, Tehran 1445613131, Iran

[2] Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, Omaha, NE USA

来源：

EYE | 2013年 / 27卷 / 07期

关键词：

intravitreal injection; anti-vascular endothelial growth factor; bevacizumab; ranibizumab; aflibercept; safety; PIGMENT EPITHELIAL TEARS; ISCHEMIC OPTIC NEUROPATHY; BEVACIZUMAB AVASTIN; INTRAOCULAR-PRESSURE; RANIBIZUMAB LUCENTIS; RETINAL-DETACHMENT; HEMORRHAGIC COMPLICATIONS; COATS-DISEASE; SILICONE OIL; ENDOPHTHALMITIS;

D O I：

10.1038/eye.2013.107

中图分类号：

R77 [眼科学];

学科分类号：

100212 [眼科学];

摘要：

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

引用

页码：787 / 794

页数：8

共 87 条

[1]

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy [J].

Arevalo, J. F. ;

Maia, M. ;

Flynn, H. W., Jr. ;

Saravia, M. ;

Avery, R. L. ;

Wu, L. ;

Farah, M. Eid ;

Pieramici, D. J. ;

Berrocal, M. H. ;

Sanchez, J. G. .

BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (02) :213-216

[2]

Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab [J].

Bakri, S. J. ;

Pulido, J. S. ;

McCannel, C. A. ;

Hodge, D. O. ;

Diehl, N. ;

Hillemeier, J. .

EYE, 2009, 23 (01) :181-185

[3]

Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema [J].

Boehm, Michael R. R. ;

Uhlig, Constantin E. .

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2011, 249 (07) :1099-1101

[4]

Brouzas D, 2009, CLIN OPHTHALMOL, V3, P457

[5]

Isolated Sixth Nerve Palsy After Intravitreal Bevacizumab Injection [J].

Cakmak, Hasan Basri ;

Toklu, Yasin ;

Yorgun, Mucella Arikan ;

Simsek, Saban .

STRABISMUS, 2010, 18 (01) :18-20

[6]

Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study [J].

Campochiaro, Peter A. ;

Heier, Jeffrey S. ;

Feiner, Leonard ;

Gray, Sarah ;

Saroj, Namrata ;

Rundle, Amy Chen ;

Murahashi, Wendy Yee ;

Rubio, Roman G. .

OPHTHALMOLOGY, 2010, 117 (06) :1102-U111

[7]

RPE tears affer pegaptanib treatment in age-related macular degeneration [J].

Chang, Louis K. ;

Flaxel, Christina J. ;

Lauer, Andreas K. ;

Sarraf, David .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (07) :857-863

[8]

Tears of the retinal pigment epithelium - An old problem in a new era [J].

Chang, Louis K. ;

Sarraf, David .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (05) :523-534

[9]

PREDICTORS OF ANTI-VEGF-ASSOCIATED RETINAL PIGMENT EPITHELIAL TEAR USING FA AND OCT ANALYSIS [J].

Chiang, Allen ;

Chang, Louis K. ;

Yu, Fei ;

Sarraf, David .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2008, 28 (09) :1265-1269

[10]

Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapies [J].

Csaky, Karl ;

Do, Diana V. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (05) :647-656

← 1 2 3 4 5 6 7 8 9 →